Advanced in Acute Myeloid Leukemia (AML)

Dr. Beata H. Holkova

Hematology Oncology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
Advanced in Acute Myeloid Leukemia (AML)
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Beata Holkova is a Hematologist Oncology provider in Richmond, Virginia. Dr. Holkova is rated as an Advanced provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Primary Amyloidosis, Cardiac Amyloidosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Acute Myeloid Leukemia (AML).

Specialties
Hematology Oncology
Licenses
Legal Medicine in MI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthKeepers
  • POS

Locations

1250 E Marshall St, Internal Medicine, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2021
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

19 Total Publications

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Journal: Future oncology (London, England)
Published: March 08, 2021
Similar Doctors
Distinguished in Acute Myeloid Leukemia (AML)
Dr. Baldeep M. Wirk
Hematology Oncology | Transplant Surgery | Hematology
Distinguished in Acute Myeloid Leukemia (AML)
Dr. Baldeep M. Wirk
Hematology Oncology | Transplant Surgery | Hematology

Mcv Associated Physicians

1300 E Marshall St, 
Richmond, VA 
 (0.1 miles away)
804-828-0450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Baldeep Wirk is a Hematologist Oncology specialist and a Transplant Surgeon in Richmond, Virginia. Dr. Wirk is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Marginal Zone Lymphoma (MZL), Bone Marrow Transplant, and Bone Graft. Dr. Wirk is currently accepting new patients.

Distinguished in Acute Myeloid Leukemia (AML)
Dr. Victor Y. Yazbeck
Hematology Oncology | Hematology | Oncology
Distinguished in Acute Myeloid Leukemia (AML)
Dr. Victor Y. Yazbeck
Hematology Oncology | Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (1.9 miles away)
804-828-7929
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Victor Yazbeck is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Yazbeck is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Prolymphocytic Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy. Dr. Yazbeck is currently accepting new patients.

Distinguished in Acute Myeloid Leukemia (AML)
Dr. William B. Clark
Hematology Oncology | Hematology | Oncology
Distinguished in Acute Myeloid Leukemia (AML)
Dr. William B. Clark
Hematology Oncology | Hematology | Oncology

Mcv Associated Physicians

1300 E Marshall St, 
Richmond, VA 
 (0.1 miles away)
804-828-0450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Clark is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Clark is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Clark is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holkova's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile